223 (PB103) - Non-ATP competitive inhibition of PI3Kδ with IOA-244 shows anti-lymphoma activity

Abstract

Background: Activation of PI3 K signaling, mainly mediated via PI3Kδ,is a fundamental signaling cascade in lymphomas (Tarantelli et al, 2021). IOA-244 (IOA) is a highly selective and potent PI3Kδ inhibitor with atypical non-ATP competitive activity (Johnson et al, 2019) compared to FDA-approved PI3 K inhibitors idelalisib, copanlisib and duvelisib. IOA is in phase 1 as an immunomodulatory agent for patients with melanoma, mesothelioma, non-small cell lung cancer, myelofibrosis, and follicular and peripheral T cell lymphoma (TCL) as a single agent or in combination (NCT04328844).